Cronos (CRON) Net Income towards Common Stockholders (2019 - 2026)

Cronos' (CRON) quarterly Net Income towards Common Stockholders came in at $15.7 million in Q1 2026, up 103.43% year-on-year from $7.7 million in Q1 2025, and up 3299.8% quarter-over-quarter from -$491000.0 in Q4 2025.

Cronos (CRON) Net Income towards Common Stockholders (2019 - 2026) Analysis & Trends

Cronos' Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at $15.7 million for Q1 2026.

  • On a quarterly basis, Net Income towards Common Stockholders rose 103.43% year-over-year to $15.7 million in Q1 2026; TTM through Mar 2026 was $5.1 million, a 34.49% decrease from a year earlier, with the FY2023 full-year figure at -$4.1 million, up 69.65% from the prior year.
  • Net Income towards Common Stockholders improved to $15.7 million in Q1 2026 per CRON's latest filing, from -$491000.0 in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $28.3 million in Q3 2025 and bottomed at -$38.5 million in Q2 2025.
  • The 4-year median for Net Income towards Common Stockholders is -$856500.0 (2023), against an average of -$50000.0.
  • Across the five-year window, Net Income towards Common Stockholders sank 4710.98% in 2022 and surged 104.63% in 2023, its largest moves.
  • Year by year, Net Income towards Common Stockholders stood at -$2.7 million in 2022, then surged by 104.63% to $124000.0 in 2023, then slumped by 495.97% to -$491000.0 in 2025, then surged by 3299.8% to $15.7 million in 2026.
  • Per Business Quant, the three latest CRON Net Income towards Common Stockholders figures stand at $15.7 million (Q1 2026), -$491000.0 (Q4 2025), and $28.3 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Haleon 89.15 Bn 87.28 Bn - -
2 Teva Pharmaceutical Industries 35.89 Bn 32.15 Bn 1.97 Bn 370.00 Mn
3 Zoetis 32.49 Bn 30.55 Bn 1.62 Bn 601.00 Mn
4 Takeda Pharmaceutical 27.56 Bn 23.50 Bn 4.39 Bn -2.35 Bn
5 United Therapeutics 23.20 Bn 21.05 Bn 648.10 Mn 274.90 Mn
6 RedHill Biopharma 21.76 Bn 21.76 Bn - -
7 Viatris 20.28 Bn 18.48 Bn 1.16 Bn 176.40 Mn
8 Neurocrine Biosciences 17.74 Bn 16.43 Bn 800.70 Mn 197.90 Mn
9 Elanco Animal Health 12.58 Bn 12.15 Bn 785.00 Mn 57.00 Mn
10 Cronos 1.08 Bn 261.26 Mn 19.15 Mn 15.71 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 15.71 Mn
Dec 31, 2025 -491,000.00
Sep 30, 2025 28.32 Mn
Jun 30, 2025 -38.48 Mn
Mar 31, 2025 7.72 Mn
Dec 31, 2023 124,000.00
Sep 30, 2023 -182,000.00
Jun 30, 2023 -2.83 Mn
Mar 31, 2023 -1.22 Mn
Dec 31, 2022 -2.68 Mn
Sep 30, 2022 -3.78 Mn
Jun 30, 2022 -2.81 Mn
Dec 31, 2021 -268.63 Mn
Sep 30, 2021 82,000.00
Jun 30, 2021 -561,000.00
Mar 31, 2021 -21,000.00
Dec 31, 2020 -131,000.00
Sep 30, 2020 -473,000.00
Jun 30, 2020 -46,000.00
Dec 31, 2019 -300,000.00